Uridine Triacetate: the First Ever Chemoprotectant for 5-Fluorouacil Toxicity

Krishnan V
Additional contact information
Krishnan V: Department of Pharmacology, Saveetha Medical College, India

Current Trends in Biomedical Engineering & Biosciences, 2017, vol. 1, issue 3, 68-69

Abstract: Antimetabolites 5-Fluorouracil and capecitabine are used in many cancers including breast, colon, anal canal, etc. Toxicity of these agents is mild to severe and may be fatal, toxicity more common in high dose chemotherapy and patients with dihydropyromidine deficiency patients. Uridine triacetate approved as first ever chemoprotectant molecule to prevent 5-Fluorouracil and capecitabine toxicity.

Keywords: juniper publishers group; juniper publishers Biomedical Engineering journals; Biomedical Engineering journals list; medical devices journals; peer reviewed Biomedical Engineering journals; open access Biomedical Engineering journals; Biomedical Engineering journals impact factor; Biomedical Engineering scientific journals; Biomedical Engineering articles; scholarly Biomedical Engineering journals; juniper publishers reivew (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctbeb/pdf/CTBEB.MS.ID.555563.pdf (application/pdf)
https://juniperpublishers.com/ctbeb/CTBEB.MS.ID.555563.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctbeb:v:1:y:2017:i:2:p:68-69

DOI: 10.19080/CTBEB.2017.01.555563

Access Statistics for this article

Current Trends in Biomedical Engineering & Biosciences is currently edited by Sophia Mathis

More articles in Current Trends in Biomedical Engineering & Biosciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().